Blockchain Registration Transaction Record

Helus Pharma CEO to Present at Cantor Conference

Helus Pharma CEO Michael Halstead to speak at Cantor Healthcare Conference Sept 11. Learn about their novel serotonergic agonists for depression and anxiety.

Helus Pharma CEO to Present at Cantor Conference

This news matters because it highlights Helus Pharma's active engagement with the investment community, potentially increasing visibility and investor interest in their promising psychedelic-derived treatments for mental health. With Phase 3 data on HLP003 for major depressive disorder and a Breakthrough Therapy Designation, the company could significantly impact the treatment landscape if approved. Investors and patients alike should watch for updates from the conference as they may signal progress and future developments.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xe053c587988c2d8491b2e074a144f81c461febb262ff05f7ddb1aa43d951be49
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintsageGIEz-a6558124ecb2690484ff4aff17a3265f